


TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED
AUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED MARCH, 2013

(Rs. In Lakhs)

Particulars	3 Months ended 31-03-2013	Preceeding 3 months ended 31-12-2012	Corresponding 3 months ended 31-03-2012	Year to date figures for the current period ended 31-03-2013	Year ended 31-03-2012
	Unaudited	Unaudited	Unaudited	Audited	Audited
1. Net Sales / Income from Operations	124.82	114.53	214.37	587.58	1109.71
2. Other Income	0.62	24.10	15.44	8.72	73.89
3. Total Income	125.44	138.63	229.81	596.30	1183.60
4. Expenditure					
a. (Increase)/Decrease in stock in trade and work in Progress	16.10	(0.76)	5.75	27.19	39.69
b. Consumption of Raw Material		Nil	Nil	Nil	Nil
c. Purchase of Traded Goods	77.73	100.22	196.69	427.96	997.46
d. Employees Cost	9.14	6.66	8.09	25.94	27.41
e. Rent	1.86	1.77	1.95	6.99	7.08
f. Depreciation	6.48	6.91	6.05	26.63	26.21
g. Other Expenditure	11.13	4.22	7.39	26.17	24.39
Total	122.44	119.03	225.92	540.88	1122.24
5. Interest	0.70	0.00	0.16	0.70	0.85
6. Exceptional items	Nil	Nil	Nil	Nil	Nil
7. Profit/ (Loss) from Ordinary activities before tax (3) - (4+5+6)	2.30	19.61	3.73	54.72	60.51
8. Tax Expense (Including Deferred Tax)	0.00	8.23	(1.32)	16.98	14.10
9. Net Profit/ (Loss) from Ordinary activities after Tax (7-8)	2.30	11.38	5.05	37.74	46.41
10. Extraordinary Items	Nil	Nil	Nil	Nil	Nil
11. Net Profit/ (Loss) for the period (9-10)	2.30	11.38	5.05	37.74	46.41
12. Paid-up Equity Share Capital (Face Value of Rs.10/- each)	810.00	675.00	675.00	810.00	675.00
13. Reserves excluding revaluation reserves as per balance sheet of previous accounting year	134.02	134.02	87.47	134.02	134.02
14. Earnings Per Share (EPS)					
a. Basic and diluted EPS before extraordinary items for the period, for the year to date and for the previous year (not to be annualised)	0.03*	0.17	0.07	0.55	0.69
15. Public Share Holding					
- Number of Shares	3366200	2016200	2016200	3366200	2016200
- Percentage of shareholding	41.56%	29.87%	29.87%	41.56%	29.87%
16. Promoters and promoter group shareholding					
a. Pledged / encumbered					
- No of Equity Shares	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil
a. Non encumbered					
- No of Equity Shares	4733800	4733800	4733800	4733800	4733800
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	58.44%	70.13%	70.13%	58.44%	70.13%

* Weighted Average Number of Equity Shares considered

For Trimurthi Drugs & Pharmaceuticals Limited



Managing Director



TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED
AUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED MARCH, 2013

Segment Reporting

Particulars	Quarters ended			Year ended	Year ended
	31/03/2013	31/12/2012	31/03/2012	31/03/2013	31/03/2012
	Unaudited	Unaudited	Unaudited	Audited	Audited
1. Segment Revenue					
a. Pharma Business	106.63	118.75	216.88	525.25	1117.10
b. Financial Services	18.81	16.59	12.90	70.75	59.65
c. Investments	0.00	25.03	0.00	50.80	6.85
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00
Total	125.44	160.37	229.78	646.80	1183.60
2. Segment Profits					
a. Pharma Business	(14.49)	1.53	(7.07)	(9.50)	1.40
b. Financial Services	16.79	17.79	10.79	63.93	52.27
c. Investment	0.00	0.29	0.00	0.29	6.85
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00
Total	2.30	19.61	3.72	54.72	60.52
3. Capital Employed					
a. Pharma Business	372.00	364.36	299.55	372.00	268.32
b. Financial Services	664.88	567.23	409.82	664.88	410.17
c. Investments	2.00	8.00	50.54	2.00	50.54
d. Trading in Shares	0.00	0.00	0.00	0.00	Nil
Total	1038.88	939.59	759.91	1038.88	729.02

Notes:


- The above results have been taken on record by the board of directors of the company at their meeting held on 26/04/2013.
- The financial results for the quarter ended 31-03-2013 have been reviewed by the statutory auditors in pursuance of listing agreement.
- In segment reporting common assets that are used interchangeable not allocated to the individual segment above.
- The status of investor grievances for the quarter ended 31/03/2013:
 - pending at the beginning - Nil
 - received - 1
 - settled - 1
 - pending at the end - Nil

Place : Hyderabad,
Date : 26/04/2013.

For Trimurthi Drugs & Pharmaceuticals



Managing Director





Trimurthi Drugs & Pharmaceuticals Ltd.

Date: 26-04-2013

To
The Secretary,
The Bombay Stock Exchange Limited,
Flor 25, P.J.Towers,
Dalal Street,
Mumbai.

Sir,

Sub: Outcome of board meeting held on 26-04-2013.

With reference to the subject cited, this is inform the Exchange that at the Board meeting of M/s. Trimurthi Drugs & Pharmaceuticals Ltd held on Friday, 26-04-2013 at the registered office of the company the following were duly considered and approved by the Board.

1. Un-audited financial results for the quarter ended 31-03-2013. (attached)
2. Limited Review Report for the quarter ended 31-03-2013. (attached)

Thanks & Regards,

Yours Truly,
For Trimurthi Drugs & Pharmaceuticals Ltd.,

Arvind Kumar Bhangadia
Managing Director

Encl: as above



Trimurthi Drugs & Pharmaceuticals Ltd.

32

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED UN-AUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED MARCH, 2013

(Rs. In Lakhs)

Particulars	3 Months ended 31-03-2013	Preceding 3 months ended 31-12-2012	Corresponding 3 months ended 31-03-2012	Year to date figures for the current period ended 31-03-2013	Year ended 31-03-2012
	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Net Sales / Income from Operations	107.11	114.53	214.37	517.92	1109.71
2. Other Income	22.86	24.10	15.44	82.91	73.89
3. Total Income	129.97	138.63	229.81	600.83	1183.60
4. Expenditure					
a. (Increase)/Decrease in stock in trade and work in Progress	16.09	(0.76)	5.75	27.19	39.69
b. Consumption of Raw Material	Nil	Nil	Nil	Nil	Nil
c. Purchase of Traded Goods	76.95	100.22	196.69	427.17	997.46
d. Employees Cost	9.09	6.66	8.09	25.89	27.41
e. Rent	1.86	1.77	1.95	6.99	7.08
f. Depreciation	6.80	6.91	6.05	26.95	26.21
g. Other Expenditure	7.33	4.22	7.39	22.37	24.39
Total	118.13	119.03	225.92	536.57	1122.24
5. Interest	0.00	0.00	0.16	0.00	0.85
6. Exceptional items	Nil	Nil	Nil	Nil	Nil
7. Profit/ (Loss) from Ordinary activities before tax (3) - (4+5+6)	11.85	19.61	3.73	64.27	60.51
8. Tax Expense (Including Deferred Tax)	2.95	8.23	(1.32)	19.93	14.10
9. Net Profit/ (Loss) from Ordinary activities after Tax (7-8)	8.89	11.38	5.05	44.33	46.41
10. Extraordinary Items	Nil	Nil	Nil	Nil	Nil
11. Net Profit/ (Loss) for the period (9-10)	8.89	11.38	5.05	44.33	46.41
12. Paid-up Equity Share Capital (Face Value of Rs.10/- each)	810.00	675.00	675.00	810.00	675.00
13. Reserves excluding revaluation reserves as per balance sheet of previous accounting year	134.02	134.02	87.47	134.02	134.02
14. Earnings Per Share (EPS)					
a. Basic and diluted EPS before extraordinary items for the period, for the year to data and for the previous year (not to be annualised)	0.13*	0.17	0.07	0.64	0.69
15. Public Share Holding					
- Number of Shares	3366200	2016200	2016200	3366200	2016200
- Percentage of shareholding	41.56%	29.87%	29.87%	41.56%	29.87%
16. Promoters and promoter group shareholding					
a. Pledged / encumbered					
- No of Equity Shares	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil
- Percentage of Shares (of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil
a. Non encumbered					
- No of Equity Shares	4733800	4733800	4733800	4733800	4733800
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	58.44%	70.13%	70.13%	58.44%	70.13%

* Weighted Average Number of Equity Shares considered

For Trimurthi Drugs & Pharmaceuticals Ltd

Managing Director



Trimurthi Drugs & Pharmaceuticals Ltd.

33

TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED UN-AUDITED QUARTERLY RESULTS FOR THE QUARTER ENDED MARCH, 2013

Segment Reporting

Particulars	Quarters ended			Year ended	Year ended
	31/03/2013 Unaudited	31/12/2012 Unaudited	31/03/2012 Unaudited	31/03/2013 Unaudited	31/03/2012 Audited
1. Segment Revenue					
a. Pharma Business	108.21	118.75	216.88	526.84	1117.10
b. Financial Services	21.76	16.59	12.90	73.70	59.65
c. Investments	(7.91)	25.03	0.00	50.83	6.85
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00
Total	122.06	160.37	229.78	651.37	1183.60
2. Segment Profits					
a. Pharma Business	(7.64)	1.53	(7.07)	(2.65)	1.40
b. Financial Services	19.49	17.79	10.79	66.63	52.27
c. Investment	0.00	0.29	0.00	0.29	6.85
d. Trading in Shares	0.00	0.00	0.00	0.00	0.00
Total	11.85	19.61	3.72	64.27	60.52
3. Capital Employed					
a. Pharma Business	339.79	364.36	299.55	339.79	268.32
b. Financial Services	694.68	567.23	409.82	694.68	410.17
c. Investments	11.00	8.00	50.54	11.00	50.54
d. Trading in Shares	0.00	0.00	0.00	0.00	Nil
Total	1045.48	939.59	759.91	1045.48	729.02

Notes:

- The above results have been taken on record by the board of directors of the company at their meeting held on 26/04/2013.
- The financial results for the quarter ended 31-03-2013 have been reviewed by the statutory auditors in pursuance of listing agreement.
- In segment reporting common assets that are used interchangeable not allocated to the individual segment above.
- The status of investor grievances for the quarter ended 31/03/2013:
 - pending at the beginning - Nil
 - received - 1
 - settled - 1
 - pending at the end - Nil

Place : Hyderabad,
Date : 26/04/2013.

Trimurthi Drugs & Pharmaceuticals Ltd.

Managing Director: